Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.
about
Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal CancerOncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancerERK2-Dependent Phosphorylation of CSN6 Is Critical in Colorectal Cancer DevelopmentEpidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacyFrom bench to bedside: lessons learned in translating preclinical studies in cancer drug developmentHarnessing soluble NK cell killer receptors for the generation of novel cancer immune therapy.EGFR Targeting in Hormone-Refractory Prostate Cancer: Current Appraisal and Prospects for Treatment.Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer.Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximabAdverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancerThe effect of combination anti-endothelial growth factor receptor and anti-vascular endothelial growth factor receptor 2 targeted therapy on lymph node metastasis: a study in an orthotopic nude mouse model of squamous cell carcinoma of the oral tongNew approaches in angiogenic targeting for colorectal cancer.Epidermal growth factor receptor inhibitors in colorectal cancer treatment: what's new?MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signalsp38 MAP kinase mediates stress-induced internalization of EGFR: implications for cancer chemotherapy.Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma.Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors.In vivo topoisomerase I inhibition attenuates the expression of hypoxia-inducible factor 1α target genes and decreases tumor angiogenesis.Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation.Synergistic Inhibitory Effects of Cetuximab and Cisplatin on Human Colon Cancer Cell Growth via Inhibition of the ERK-Dependent EGF Receptor Signaling Pathway.Tetrathiomolybdate mediates cisplatin-induced p38 signaling and EGFR degradation and enhances response to cisplatin therapy in gynecologic cancers.Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status.Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatmentA simple and reproducible scoring system for EGFR in colorectal cancer: application to prognosis and prediction of response to preoperative brachytherapy.Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126.Induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trialCetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial.Antitumor effect of cetuximab in combination with S-1 in EGFR-amplified gastric cancer cellsPrincipal component analysis for the comparison of metabolic profiles from human rectal cancer biopsies and colorectal xenografts using high-resolution magic angle spinning 1H magnetic resonance spectroscopy.Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model.Role of Reactive Oxygen Species in the Abrogation of Oxaliplatin Activity by Cetuximab in Colorectal Cancer.A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer.Targeted therapeutic agents for colorectal cancer.EGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality.A Phase II study of cetuximab (Erbitux) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer.Cetuximab in the management of colorectal cancer.Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer.Evolvement of the treatment paradigm for metastatic colon cancer. From chemotherapy to targeted therapy.A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer.
P2860
Q26748924-D94D8A88-C181-4AE3-AFDF-06498C048F80Q28077545-CB62912D-CEAF-45DF-B677-81E18E469CEBQ28115416-0BD7C589-438F-4FB7-99DB-177E2D7350ECQ28475894-3A2DF6CC-4C1C-42D5-9F3A-E9F1A4930C53Q28533949-02DAB3B0-A29A-4A80-9A3B-B2E6E274F30EQ33334362-E838853A-2955-42C1-92A8-92AF27C9EEC7Q33677975-C251A511-E9A2-41D5-BA53-EC27EB86A9CFQ33684453-E68970F4-E314-4211-9D31-040A7D52A64AQ33842323-67A235E1-9B37-4F15-A628-2ECB986F13A8Q33983656-D0A51632-D433-4E6D-B1EF-340F2EB4E864Q34039015-4F0C48DF-91E4-4472-AA08-55F0ED08C0A9Q34382785-74C373D0-9731-4C4B-A1B0-F78411DD8FB0Q34382797-C32732FA-ABA8-4A68-BC1C-922EEBA7A616Q34721752-47184003-E7F2-49C4-983E-14D0B353DA68Q35039999-1BDC7363-67B9-45A7-833F-6EA5573D9042Q35154219-A44B2956-DF7A-41E8-85FE-FC4B776F6D0CQ35597039-9E6818FB-93EF-416F-89C5-6FD2582DE6A9Q35647847-0E72CC8B-CCF4-4293-A710-82D56B9E7F94Q35718945-91413EE2-022C-476A-A4A1-40EC5E754877Q35962555-9CE8E6FE-11BA-4233-9C6F-B4B5A7E88B7FQ36146089-14D2C914-11FF-4668-B129-335AEB05092EQ36280333-2D59C450-8C61-429F-A6A0-D7AAC3BE5A85Q36484536-C4E011DD-A1F5-4DBD-AF52-98C0098992BAQ36609698-78F596B8-2E36-4228-992B-492C70EC6919Q36609946-80957349-209A-4A2D-85BD-99B0E38F1A1BQ36611627-FDD314C8-2E8C-4830-B2A4-011F1F740FA2Q36611661-0835F8D5-FD44-4124-9501-D88D54101658Q36614517-6B036C71-97BC-4A7F-8E4B-5CE985BB2ADBQ36645690-9992BCC7-FD18-40F8-8325-B7B6B43E4D65Q36649292-1144B032-D626-4277-A66D-F26BEAF82608Q36755155-B34B8FF7-3F46-40FA-8559-A066519F5DA1Q36895532-966F1BC8-EF6A-4D46-A55E-23DC43D188C9Q36973778-E3C286B2-C0E6-436A-AC6B-8244DAE6E46EQ37158228-D3604DBB-BB79-4C29-A87F-7B3602D4919DQ37174372-561303F4-82A3-4A06-9DBB-BB0E48E580F4Q37222532-AEE82C51-6B8F-42B3-A71F-06B52CA7AC40Q37290499-BD897D49-CF77-4263-815E-F363B759F073Q37299843-CAAFC2A6-F7D6-4BBF-828A-363EF9F3F55BQ37360585-03348A35-A0F1-45C3-833B-99625F8296AAQ37481363-9274ACD6-59AE-4A5B-A1BF-3B0622EB27F4
P2860
Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Enhanced antitumor activity of ...... n colorectal tumor xenografts.
@ast
Enhanced antitumor activity of ...... n colorectal tumor xenografts.
@en
Enhanced antitumor activity of ...... in combination with irinotecan
@nl
type
label
Enhanced antitumor activity of ...... n colorectal tumor xenografts.
@ast
Enhanced antitumor activity of ...... n colorectal tumor xenografts.
@en
Enhanced antitumor activity of ...... in combination with irinotecan
@nl
prefLabel
Enhanced antitumor activity of ...... n colorectal tumor xenografts.
@ast
Enhanced antitumor activity of ...... n colorectal tumor xenografts.
@en
Enhanced antitumor activity of ...... in combination with irinotecan
@nl
P2093
P1476
Enhanced antitumor activity of ...... n colorectal tumor xenografts.
@en
P2093
Andrea T Hooper
Daniel J Hicklin
Harlan W Waksal
Lee M Ellis
Marie C Prewett
Rajiv Bassi
P304
P407
P577
2002-05-01T00:00:00Z